Treatment with CAR T cells was recently approved by the FDA on basis of clinical efficacy in B-cell malignancies. CARs are immune receptors generated from antibodies that recognize cell surface proteins, whereas T-cell receptors can recognize peptides from any cellular protein. A limitation for development of immune-gene therapy in the majority of cancer types is the scarcity of molecules that can be targeted in a safe and efficacious manner by CARs or T-cell receptors. Thus, there is a need for high-throughput strategies to identify therapeutic targets and their cognate T-cell receptors and antibodies.
What will be discussed:
Johanna Olweus, Professor, Director, K.G. Jebsen Center for Experimental Immunotherapy, University of Oslo
What will be discussed?
Elisa Scarselli, CSO , Nouscom